Choosing between Mounjaro versus Wegovy is not simply a matter of picking the treatment associated with the biggest number on a scale. Both are prescription weight-management medicines, both are taken once weekly, and both can support meaningful weight loss alongside dietary and activity changes. The better choice is the one that fits your medical history, goals, side-effect tolerance and practical routine – with a UK clinician involved from the start.
Mounjaro versus Wegovy at a glance
Mounjaro contains tirzepatide. It works on two natural hormone pathways, GIP and GLP-1, which help regulate appetite, food intake and blood sugar. For many people, this means feeling fuller sooner, staying full for longer and finding it easier to eat smaller portions.
Wegovy contains semaglutide and works on the GLP-1 pathway. It has a similar appetite-regulating effect, slowing the movement of food through the stomach and helping reduce hunger and cravings. Wegovy has been used for weight management in the UK for longer, while Mounjaro has become a widely considered option because of the results seen in clinical trials.
Neither treatment is a quick fix or a replacement for food, movement, sleep and support. They can, however, make the day-to-day changes that underpin weight loss feel more achievable for people who have repeatedly struggled despite genuine effort.
Who can be prescribed these medicines?
In the UK, Mounjaro and Wegovy are licensed for weight management in adults with a body mass index (BMI) of 30 kg/m² or above. They may also be suitable from a BMI of 27 kg/m² where there is a weight-related health condition, such as high blood pressure, abnormal blood fats, obstructive sleep apnoea, prediabetes or type 2 diabetes.
Eligibility is more detailed than a BMI calculation. A prescriber will consider your weight history, current medicines, medical conditions and previous experience with weight-management treatment. They will also check whether the medicine is safe and appropriate for you.
These treatments are not appropriate during pregnancy or breastfeeding. They may not be suitable for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, and extra care is needed where there is a history of pancreatitis, gallbladder disease, severe digestive illness or diabetic eye disease. A consultation should be honest and complete, even when a health concern feels unrelated to weight.
Which produces greater weight loss?
This is often the first question people ask, and it deserves a careful answer. Clinical trials have shown substantial average weight loss with both treatments when combined with lifestyle support. Results vary considerably between individuals.
Mounjaro has shown greater average weight loss than Wegovy in a direct head-to-head study involving adults living with obesity or overweight without diabetes. At 72 weeks, participants taking tirzepatide lost an average of around 20% of their starting body weight, compared with around 14% for those taking semaglutide, when using the highest tolerated doses.
That does not mean Mounjaro will be the right treatment for every person, or that an individual will lose exactly that amount. Trial participants received structured support and were followed closely. Your starting weight, dose tolerance, health conditions, eating patterns, activity, stress and consistency with treatment all affect outcomes.
A medicine that you can tolerate, take consistently and use with appropriate clinical support is usually more valuable than chasing a headline figure. Weight loss also commonly slows over time. That is normal, not proof that treatment has stopped working.
If you have type 2 diabetes
Both medicines can affect blood glucose. Mounjaro is also licensed in the UK for type 2 diabetes under its brand name, while Wegovy is specifically licensed for weight management. If you use insulin or medicines such as sulphonylureas, your diabetes treatment may need review to reduce the risk of low blood sugar.
For some people, glucose control, cardiovascular risk and other health priorities will carry as much weight as the number of kilograms lost. This is one reason a clinician-led assessment matters.
Dosing: similar routine, different dose schedules
Both Mounjaro and Wegovy are supplied as once-weekly injections. They are usually injected under the skin of the stomach, thigh or upper arm, on the same day each week. You begin on a lower dose and increase gradually, typically every four weeks, to help your body adjust.
Wegovy starts at 0.25 mg weekly and is gradually increased to a usual maintenance dose of 2.4 mg. Mounjaro starts at 2.5 mg weekly, with stepwise increases available up to 15 mg weekly. Your prescriber may recommend staying at a lower dose for longer if side effects are troublesome, or may decide that a higher dose is not needed.
The pen format and exact instructions differ, so it is worth reading the patient information leaflet and following your pharmacy’s guidance rather than assuming the injections work identically. Do not change doses, double up after a missed dose or switch directly between medicines without clinical advice.
Side effects: what to expect and when to seek help
The most common side effects of both medicines are digestive. Nausea, diarrhoea, constipation, vomiting, indigestion and abdominal discomfort are most likely when starting treatment or increasing the dose. For many people, these settle as the body adapts.
Smaller meals, eating slowly, stopping when comfortably full and keeping hydrated can help. Rich or very fatty meals and large portions can make nausea worse. If symptoms are persistent, severe or affecting your ability to drink fluids, contact your prescriber promptly rather than trying to push through.
Seek urgent medical advice for severe, persistent stomach pain, particularly if it spreads to your back or comes with vomiting, as this could indicate pancreatitis. Symptoms of an allergic reaction, such as swelling of the face or throat, breathing difficulty or a widespread rash, also need urgent care.
There are practical differences to discuss too. Mounjaro can reduce the effectiveness of oral contraceptive pills when you first start it and after each dose increase. If you use the pill, you may be advised to use a barrier method or switch to a non-oral contraceptive method for four weeks after starting and for four weeks after each dose escalation. Your clinician can provide advice specific to your contraception.
If you are planning pregnancy, treatment should be stopped in advance. The recommended timeframe differs between medicines, so ask your prescriber for individual advice before trying to conceive rather than stopping at the last minute.
When Wegovy may be the more suitable choice
Wegovy may suit someone who has previously used semaglutide successfully, is comfortable with its dose schedule or has a clinical reason to remain with a GLP-1-only treatment. Familiarity and tolerability count. A treatment that causes manageable side effects and supports steady progress can be a very good treatment.
It may also be the preferred option where a clinician judges that your other medicines, health history or contraception needs make it more straightforward. The decision should never be based on social-media claims or a friend’s experience alone.
When Mounjaro may be the more suitable choice
Mounjaro may be considered when a person is seeking the greater average weight-loss outcomes shown in studies and is clinically suitable for tirzepatide. It can also be an option for people with type 2 diabetes whose wider treatment plan may benefit from tirzepatide’s effects on blood glucose.
That said, stronger average trial results do not remove the need to manage side effects, eat enough protein and fibre, protect muscle through appropriate activity, and attend to emotional or habit-driven eating. The injection can reduce appetite, but it cannot build a sustainable routine on its own.
Choosing with ongoing clinical support
The first prescription is only one part of safe weight-management care. A good service checks your suitability, explains how to use your treatment, reviews progress and gives you a clear route back to a clinician if something changes. This matters when doses are increased, side effects develop, weight loss stalls or another medicine is prescribed.
At Online UK Pharmacy, treatment requests are reviewed by UK clinicians and dispensed by a regulated pharmacy, with discreet plain-packaged delivery. It is care designed to be convenient without making a personal health decision feel automated.
Before choosing, be ready to share your current weight and health conditions, full medication list, pregnancy plans, previous weight-loss attempts and what you want treatment to help you change. The most useful question is not only, “Which one works best?” It is, “Which option can I use safely and stick with, with the right support around me?”
